FINWIRES · TerminalLIVE
FINWIRES

Strong Industrial Profit Data Boosts Chinese Shares; Moore Threads Technology Jumps 8%

By

Chinese shares rose on Monday as strong first-quarter industrial profit data boosted investor sentiment.

The Shanghai Composite Index, the main gauge of Chinese stocks, rose 0.2% to 4,086.34. The Shenzhen Component Index climbed 0.4% to 14,995.75.

The total profits of China's industrial enterprises in the first quarter jumped 15.5% year on year to 1.696 trillion yuan.

Profits in the mining industry rose 16.2% from a year earlier to 256.33 billion yuan, while that of the manufacturing industry climbed 19.1% to 1.238 billion yuan. The utilities industry's profits slipped 3.2% year on year to 201.3 billion yuan.

The profits of the technology industry and the non-ferrous metal industry both rose 1.2 times.

In company news, Moore Threads Technology (SHA:688795) swung to an attributable net profit of 29.4 billion yuan in the first quarter of 2026 from a net loss of 112.5 million yuan a year prior. Shares of the graphics processing unit manufacturer closed 8% higher Monday.

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA